Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of elranatamab monotherapy versus investigator's choice regimens in relapsed/refractory multiple myeloma after prior anti-CD38 therapy
MOH_2025-01-28_013753Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Jan 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of elranatamab in multiple myeloma (MM) (2 arms), sponsored by Pfizer. Started Jan 2025; status: recruiting.
02
Drugs
elranatamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on MOH_2025-01-28_013753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-01-28_013753.